Table 3.
Productivity Loss and Associated Costs of Multiple Myeloma Patients Receiving Treatment
| Oral Chemotherapy Users (n = 73) | Injectable Chemotherapy Users (n = 226) | P Valuea | |
|---|---|---|---|
| Benefit users before diagnosis, n (%) | 0.707 | ||
| WAB | 18 (24.7) | 52 (23.0) | |
| STD | 6 (8.2) | 24 (10.6) | |
| LTD | 0 (0) | 1 (0.4) | |
| Benefit users after diagnosis, n (%) | 0.830 | ||
| WAB | 17 (23.3) | 46 (20.4) | |
| STD | 35 (48.0) | 108 (47.8) | |
| LTD | 5 (6.9) | 19 (8.4) | |
| Predicted number of missed work days in year after MM diagnosis,b days (95% CI) | 87.2 (79.2-95.3) | 109.7 (95.3-120.0) | < 0.001 |
| Predicted costs of missed work in year after MM diagnosis,b USD (95% CI) | $14,605 ($13,312-$15,900) | $18,500 ($16,862-$20,139) | < 0.001 |
aChi-square test was used to evaluate categorical variables.
bParameter estimates from multivariable zero-inflated Poisson regression.
CI = confidence interval; LTD = long-term disability; MM = multiple myeloma STD = short-term disability; USD = U. S. dollars; WAB = workplace absenteeism.